- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Avisio Granted License With Exclusive Acquisition Rights to Commercialize Portable Nano-Based Diagnostic Technology.
Avisio, Inc. (Pinksheets:AVIC - News) announces the signing of a definitive agreement to commercialize Instant Detect, a portable nano-based diagnostic technology. Avisio, a publicly-traded commercialization company with a mission to unlock the value of high-potential assets and transform them into high-value businesses, now has the worldwide license to commercialize Instant Detect's ground-breaking portable diagnostic sensory technology. With the agreement, Avisio has exclusive acquisition rights for 18 months.
Instant Detect's sensory technology will be incorporated into a highly sensitive handheld instrument designed for use in the field. Using nanosensors, the technology allows for the testing of viruses, bacteria and other disease-causing pathogens in a non-laboratory environment, with immediately available results that do not require the expertise of a specialized lab technician to read.
Among potential uses envisioned for the technology, professional individuals will ultimately be able to instantly detect such disease-causing pathogens as H1N1, West Nile Virus, dengue, malaria and encephalitis among at risk populations, while agricultural inspectors will be able to detect pathogens in the food supply and farmers will be able to detect plant diseases and livestock pathogens instantly. The device will require no specialized training and can detect pathogens from a broad range of samples.
Avisio intends to make the product commercially available in the second half of 2010.
Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based largely on expectations and projections about future events and future trends and are subject to numerous assumptions, risks and uncertainties, which change over time. Avisio's actual results could differ materially from those anticipated in forward-looking statements and you should not place any undue reliance on such forward-looking statements.
The forward-looking statements in this news release are made as of the date hereof, and Avisio does not assume any obligation to update, amend or clarify them to reflect events, new information or circumstances occurring after the date hereof.
Avisio, Inc. is a publicly-traded commercialization company with a mission to unlock the value of high-potential assets and transform them into high-value businesses. Avisio plans to create a new majority-owned private subsidiary around each asset and to support each business with experienced management teams, best-of-breed commercialization processes and resources, and access to global capital sources.
For more information, please click here
Copyright © AvisioIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Explaining how 2-D materials break at the atomic level January 20th, 2017
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
GLOBALFOUNDRIES Expands Partner Program to Speed Time-to-Market of FDX™ Solutions: Increased support affirms FDXcelerator™ Program’s vital role in promoting broader deployment of GLOBALFOUNDRIES’ FDX™ portfolio December 15th, 2016
Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016